Ján Staško, Miroslava Dobrotová, Jela Ivanková, Lucia Stančiaková, Zuzana Jedináková, Juraj Sokol, Ingrid Škorňová, Ľubica Kořínková, Peter Kubisz
Many large clinical trials have been published in the past few years showing the new oral anticoagulant drugs (NOAC)
generally safe and effective in several clinical settings including acute venous thromboembolic disease, prophylaxis in
the postoperative setting, prevention of thromboembolism in patients with non-valvular atrial fibrillation, and in the
management of acute coronary syndromes. The relatively short half-life, rapid onset of action, and predictable pharmacokinetics
should simplify periprocedural use of NOAC. This review aims to provide a practical, clinician-focused approach
to periprocedural anticoagulant management with NOAC.